Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04751396 · ClinicalTrials.gov registry record
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
A clinical trial of Melanoma and Psoriasis, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT04751396 is a study of Melanoma and Psoriasis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 125 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04751396, a study of Melanoma and Psoriasis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Questionnaire Administration
- OTHER Best Practice
- OTHER Educational Intervention
- OTHER Interview
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2027-02-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04751396
The ClinicalTrials.gov registry entry for NCT04751396 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (82% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Survey Administration is the first listed.
NCT04751396 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04751396 about?
NCT04751396 is a clinical study titled "Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors". This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of t...
What is the current status of trial NCT04751396?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2022-04-20. Estimated completion is 2027-02-02.
What conditions does trial NCT04751396 study?
This clinical trial studies the following conditions: Melanoma, Psoriasis, Crohn Disease, Psoriatic Arthritis, Inflammatory Bowel Disease.
What interventions are being tested in trial NCT04751396?
The interventions under investigation include: Survey Administration (OTHER), Questionnaire Administration (OTHER), Best Practice (OTHER), Educational Intervention (OTHER), Interview (OTHER).
Who is sponsoring clinical trial NCT04751396?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04751396 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.